Abstract: Embodiments of a composition provide a line of defense against SARS coronaviruses that complements vaccines. The composition may be taken orally, intravenously, nasally, or inhaled by a healthy person to prevent a SARS infection or by a sick person infected by a SARS coronavirus for treatment. The composition is configured for molecular pattern recognition based targeting of the SARS coronavirus spike (S) protein and activating an innate immune response. The composition includes a lectin component. The composition may also include an optional flavonoid component, an optional calcium component, or both.

Abstract: Central blood pressure parameters are monitored using a smart watch or smart band. A PPG sensor on the smart watch or smart band is adapted to sense blood perfusion in the finger (or lower wrist/radial artery) of the person wearing the smart watch or smart band. The PPG signal captures cardiovascular features which can be detected after proper filtering and processing. Signal processing, using the transfer function method, results in an un-calibrated central pressure waveform, which can be used to calculate various cardiovascular parameters or indicators of the parameters that are displayed on the smart watch or smart band. Digital signal processing can be implemented on the smart watch or smart band, on a smart phone, laptop or in the Cloud.

Abstract: The present disclosure provides methods for treating autosomal dominant diseases in a subject. In some aspects, the methods involve the use of a gene editing enzyme with a pair of unique guide RNA sequences that targets both mutant and wildtype forms of autosomal dominant disease-related gene for destruction in cells, and then supplying the cells with wildtype autosomal dominant disease-related gene cDNA which is codon modified to evade recognition by the guide RNAs. These methods are broadly applicable to any autosomal dominant disease.

Abstract: The present disclosure relates to a combination treatment for inflammatory diseases. Specifically, the treatment described herein involves administering to a subject suffering from an inflammatory disease a combination of an anti-TNF-alpha inhibitor and at least one small molecule anti-inflammatory agent, to treat the inflammatory disease.

Abstract: Accelerometers and capacitive touch sensors fabricated from inexpensive, lightweight, disposable substrate materials, such as paper, are provided. These can be fabricated using simple technologies, such as laser cutting and screen printing. In one embodiment, a touch sensor includes a parallel plate capacitor having a fixed plate formed of a substrate material having a conductive layer and a deflectable plate formed of a paper substrate material having a conductive layer. In a second embodiment, a touch sensor includes a parallel plate capacitor formed of an exterior conductive layer deposited on a paper substrate material and an interior conductive layer deposited on a substrate material. In a third embodiment, a touch sensor includes an active electrode and a grounded electrode patterned on the surface of a paper substrate material. In another embodiment, an accelerometer includes a parallel plate capacitor containing a fixed plate and a free plate containing a paper substrate.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: A multiple sensitivity stud sensing device for determining a location of objects behind a wall lining has a housing with a surface for moving over the wall lining. Within the housing are a capacitive sensor with first and second capacitances provided adjacent the surface and control circuitry. The control circuitry includes a detecting circuit connected to the sensor for providing a detection signal related to an imbalance between the first and second capacitances, a processor for receiving the detection signals signal and providing a display signal. A display is provided on the housing for indicating a location of an object behind the wall lining. The processor compares the detection signal to stored predetermined threshold values of detection signals associated with different wall lining thickness and displays a thickness value to the user.

Abstract: The present invention is directed to compositions of an islet cell differentiation transcription factor polypeptide, or any of its homologs or orthologs, as a therapeutic agent for the treatment of diabetes, more specifically insulin-dependent diabetes. The methods and compositions of the present invention provide an increase in glucose tolerance, an increase in insulin, and/or an increase in insulin-producing cells in the host.

Abstract: An in vivo assay system for identifying chemical compounds that inhibit or promote a biological event is described. Test compounds may be assayed for their ability to induce the expression of a reporter gene which subsequently leads to the production of a reporter gene product. Preferably the reporter gene product is secreted from the cell or is membrane permeable so that the product is readily detectable. The signal from the reporter gene is preferably amplifiable so that even minute changes in expression of the reporter gene are detectable. The present invention also provided combinatorial libraries for use in the inventive assay system.

Abstract: Dioxane derivatives for use as components in liquid crystal devices (LCDs) of general formula (A), wherein X is CH or B; R.sup.1, R.sup.2 are each A.sup.1, OA.sup.1, OCOA.sup.2, or COOA.sup.2 ; A.sup.1 is a straight or branched chain alkyl group containing from 1 to 20 carbon atoms and may be substituted with one or more F or CN. A.sup.2 is a straight or branched chain alkyl group containing from 1 to 20 carbon atoms and may be substituted with one or more F or CN and if straight may be unsubstituted. Y.sup.1, Y.sup.2, Y.sup.3 may each be (CH.sub.2).sub.p, (CH.sub.2).sub.p COO or OCO(CH.sub.2).sub.p ; p is from 0 to 10, n is 0 or 1, m is 0 or 1, either or both of Z.sub.1 and Z.sub.2 are F and, when not F, are H; Y.sup.4 is a covalent bond or, when n is 0, may be (a) LCDs, containing the devices exhibit very fast switching speed, bi-stable characteristics, enhanced greyscale and storage capabilities and a wide viewing angle.